Mechanism of Action of BTK Inhibitors in Chronic Lymphocytic Leukemia

News
Video

Susan O’Brien, MD, provides a brief overview of chronic lymphocytic leukemia (CLL), and Seema Ali Bhat, MD, explains the mechanism of BTK inhibitors.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content
Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Evaluating Single-Agent Ziftomenib’s Performance in NPM1+ R/R AML

Tim Cortese
September 16th 2025
Article
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

Elizabeth Shpall, MD
September 16th 2025
Podcast
Chronic myeloid leukemia was once known as a deadly disease, renowned for its difficulty to treat.

Recapping A Quarter Decade of Chronic Myeloid Leukemia Therapy

Tim Cortese
September 16th 2025
Article
Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

Naval Daver, MD
September 16th 2025
Podcast
No minimal residual disease-negativity was observed with tuspetinib in patients with AML, including in a patient with more than 7 months of follow-up data.

Tuspetinib Exhibits Enhanced Efficacy in Diverse Newly Diagnosed AML Group

Roman Fabbricatore
September 16th 2025
Article
Leading experts gathered in Orlando, FL, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.

National ICE-T Conference Aims to Make CAR T Safer and More Available

Tim Cortese
September 16th 2025
Article